Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) saw unusually large options trading activity on Wednesday. Investors acquired 18,439 call options on the company. This is an increase of 820% compared to the average daily volume of 2,004 call options.
Roivant Sciences Stock Up 1.1 %
Shares of ROIV traded up $0.12 during midday trading on Wednesday, hitting $11.48. The stock had a trading volume of 2,752,223 shares, compared to its average volume of 5,799,323. The firm has a market cap of $8.48 billion, a price-to-earnings ratio of 2.26 and a beta of 1.24. The company has a 50 day simple moving average of $10.81 and a two-hundred day simple moving average of $10.88. Roivant Sciences has a twelve month low of $8.24 and a twelve month high of $13.24. The company has a debt-to-equity ratio of 0.07, a current ratio of 25.24 and a quick ratio of 25.24.
Roivant Sciences (NASDAQ:ROIV – Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.33. Roivant Sciences had a negative return on equity of 25.05% and a net margin of 3,484.86%. The business had revenue of $55.10 million for the quarter, compared to analyst estimates of $30.72 million. During the same quarter last year, the firm earned ($0.38) EPS. Roivant Sciences’s revenue for the quarter was up 155.1% compared to the same quarter last year. On average, analysts anticipate that Roivant Sciences will post -1.12 EPS for the current year.
Institutional Trading of Roivant Sciences
Analysts Set New Price Targets
A number of brokerages have commented on ROIV. HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a research report on Friday, May 31st. Piper Sandler lifted their price objective on Roivant Sciences from $20.00 to $22.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a research report on Tuesday, June 18th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, Roivant Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $17.10.
Read Our Latest Research Report on ROIV
About Roivant Sciences
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Articles
- Five stocks we like better than Roivant Sciences
- Airline Stocks – Top Airline Stocks to Buy Now
- Brinker International’s Price Dip is an Appetizing Entry Point
- ETF Screener: Uses and Step-by-Step Guide
- 3 Stocks That Could Beat the September Blues
- What is the Shanghai Stock Exchange Composite Index?
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.